OBJECTIVES: To assess the false-negative (FN) rate of positron emission tomography (PET)-chest computed tomography (CT) scan in clinical non-central cIA and cIB non-small-cell lung cancer (NSCLC) for mediastinal staging.
INTRODUCTION
In non-small-cell lung cancer (NSCLC) patients, mediastinal node disease detection is essential for the most appropriate treatment allocation. This concept gained importance after publication of several studies suggesting a better long-term survival with induction chemoradiotherapy prior to surgery in patients with mediastinal node involvement [1, 2] . Identifying this group of patients with metastatic mediastinal disease, otherwise potential candidates for surgical treatment, seems to be a sensible strategy.
However, mediastinal staging is complex and difficult and requires well-established guidelines to achieve acceptable accuracy with different invasive and non-invasive methods. Positron emission tomography (PET) integrated with computed tomography (CT) is perhaps the current standard for non-invasive staging in patients with potentially operable NSCLC [3, 4] , despite some controversy and unclear benefit for long-term survival [5, 6] . This tool seems to be the most accurate non-invasive method for clinical staging, particularly to rule out mediastinal and distant metastases; a high negative predictive value (NPV) is considered the most important PET-CT characteristic for mediastinal staging. If both the composite chest CT scan and PET-CT are negative, invasive staging methods can be spared, proceeding directly to thoracotomy and, theoretically, a low rate (<10%) of occult mediastinal metastases in selected cI stage patients [7] . These cases, very likely with low tumoural burden in the mediastinal nodes if both image studies have failed, are excellent candidates for adjuvant chemoradiotherapy after surgery when an unforeseen mediastinal station is intraoperatively detected [8, 9] .
Over time, some concerns regarding an unexpected high number of negative mediastinal uptake in patients with lymph nodes affected have been expressed, sometimes in several mediastinal stations [10] [11] [12] . This information makes the thoracic surgeon uncomfortable with proceeding directly to sometimes futile thoracotomies for intraoperative pN2 detection.
The goals of the study were to assess pN2 incidence among cI stage, clinically non-central NSCLC patients with negative mediastinal uptake of 18-fluoro-2-deoxy-D-glucose (18FDG) and lymph nodes smaller than 1 cm (short diameter) as measured by chest CT scan and to identify risk factors for FN PET-CT and CT scan patients, in order to improve treatment selection.
METHODS

Study design, data collection and settings
This prospective study was designed to assess the incidence of undetected mediastinal disease in non-central cI patients staged by the current standard non-invasive methods (CT and PET-CT scan). All potentially operable NSCLC patients diagnosed in our hospital during 48 months, January 2007-December 2010, and meeting the oncological and functional criteria of the hospital's lung cancer guidelines ( Fig. 1 ) and the European Society of Thoracic Surgeons (ESTS) were assessed carefully in a multidisciplinary meeting [13] . Following ESTS guidelines, all potentially operable cases had a dedicated CT scan and a PET-CT to rule out distant metastases and positive mediastinal lymph nodes [7] .
The absence of mediastinal lymph nodes with short axis ≥10 mm and negative mediastinal uptake (S max > 2.5) allows surgeons to proceed directly to thoracotomy and systematic mediastinal dissection without further invasive study for mediastinal staging. In case of cN1 suspicion (lymph node short axis >10 mm or 18FDG uptake >2.5) in central tumours or poor 18FDG tumour uptake, invasive mediastinal staging is indicated and these patients were excluded [7] . For this prospective study, central tumours were defined as a tumour in contact with the intrapulmonary main bronchi, pulmonary artery, pulmonary veins or the origin of the first segmental branches. Informed consent was obtained in all included cases and the hospital's healthcare and guidelines committee approved the lung cancer guidelines of this centre.
Eligibility criteria
Patients included were histologically diagnosed of NSCLC before or during surgery, clinically staged as cI and met the oncological and functional criteria for resectability. Exclusion criteria were stage cIIA or beyond, CT scan evidence of central tumour as defined by study criteria, previous neoadjuvant preoperative therapy (regardless of response), previous CT or PET-CT scan outside our hospital, a delay of more than 1 month between non-invasive staging and surgery, allergy to iodine contrast or hyperglycaemia >160 mg/dl on the day of the PET scan.
Chest computed tomography
Chest computed tomography (CT) scans were acquired at one breath-hold with maximum inspiration during the injection of a 100-cm 3 bolus of intravenous ionidate contrast agent from the lung apices through the upper abdomen, by standard 64-slice multidetector CT (MDCT) protocol (Somatom Sensation 64, Siemens Medical Solutions, Germany). From each data set, series were obtained for 4-to 5-mm-thick axial and coronal reconstructions. The criterion of CT definition for suspected metastasis of the lymph node was a short-axis diameter of 1.0 cm or larger.
18FDG PET-CT
Positive emission tomographic scans were performed using a PET-CT (Biograph, Siemens) with an ECAT EXACT HR+ Bi4Ge3 O12 (BGO) PET and a helicoidal CT scanner (Somatom, Emotion). Patients had fasted for 4 h before PET acquisition and blood glucose had to be less than 160 mg dl −1 before injection of 0.1 MBq kg −1 of 18FDG. Intravenous injection, using a venous line to prevent extravasation, was followed by a resting period (60 min) during which patients remained in a quiet room. No muscle relaxants were administered. Patients were in the supine position with their arms raised above their head and allowed to breathe normally during PET and CT acquisitions. Whole-body PET data were acquired in three-dimensional (3D) mode and for 5 min per bed position. PET images were reconstructed both with and without CT-based attenuation correction. The PET data were interpreted by one nuclear physician prior to surgical treatment. A 3D region of interest around the tumour was placed manually in transaxial, sagittal and coronal slices to include the entire volume of the lesion. The standardized uptake value (SUV) was calculated from measured activity, decay-corrected injected dose and patient body weight. Results were considered negative when no mediastinal localized area showed higher visual or maximum SUV uptake than the mediastinal background, and positive otherwise.
Surgery and mediastinal dissection
Posterolateral thoracotomy with anatomic pulmonary resection plus systematic mediastinal dissection was carried out by a consulting thoracic surgeon, as Keller previously described and as recommended by the ESTS [7] . All stations were resected except 4L, due to the complexity of the access through a left thoracotomy. Clinical and pathological staging was performed according to the revised (1997) TNM system and later revised following the International Association for the Study of Lung Cancer (IASLC) guidelines proposed in 2009 [14] . The different stations according to the 2009 mediastinal map were also updated by reviewing CT scan and 18FDG PET-CT images and the surgical notes.
Pathology
In patients, non-small-cell lung carcinomas (NSCLCs) were classified into more specific types such as adenocarcinoma or squamous cell carcinoma following the last WHO classification. In specimens, the most recent recommendations for adenocarcinoma classification were used. Briefly, all adenocarcinomas larger than 3 cm were considered 'adenocarcinoma' except those with lepidic predominant growth (LPA) patter as shown below; resection specimens were classified according to new categories, adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA); the classifications refer to small solitary adenocarcinomas with either pure lepidic growth (AIS) or predominant lepidic growth with <5 mm invasion (MIA). LPA was tumour either >3 cm, or with >0.5 mm of invasion. An earlier study of participants recruited through May 2009 used less specific classification and analysed a broader range of tumours. Thus, the term 'bronchioloalveolar adenocarcinoma' is no longer used. Therefore, all specimens collected since the beginning of the study were re-assessed under the present inclusion and exclusion criteria; specimens meeting the present study criteria were then evaluated using the most recent adenocarcinoma classifications [15] .
Statistics
Statistical analyses were carried out with the SPSS, version 13 (SPSS, Inc., Chicago, IL, USA). Qualitative variables were compared with the χ 2 -test or Fisher's exact test where appropriate, with significance at P < 0.05. All values in the text and tables are given as mean ± SD. The excess of risk was estimated using the Mantel-Haenszel test. The raw frequency of agreement was used to compare clinical against pathological stages and to assess the agreement. Kappa's index was used to determine agreement.
RESULTS
During the 48-month study period, 402 patients with potentially operable NSCLCs were assessed by PET-CT in our multidisciplinary meeting for mediastinal staging and/or distant metastasis detection. The study prospectively included 153 clinically staged patients, 123 (80.4%) males and 30 (19.6%) females, with a mean age of 66.6 ± 9.7 (41-83). Clinical characteristics are shown in Table 1 . Of these 153 patients, 79 (51%) were cIA and 74 (49%) were cIB. The most frequent histological type was adenocarcinoma [85 (55%) cases], followed by squamous carcinoma [62 (45%) cases]. Among the adenocarcinomas, there were 71 (83.5%) adenocarcinoma, 10 (12%) LPA and 4 (5%) MIA. The median follow-up was 22 months and was limited to patients with unforeseen pN2.
Operative mortality was 1.9%. Causes of death were postoperative pneumonia (n = 1), and postoperative adult respiratory distress and bronchial fistula related to difficulty weaning from mechanical ventilation (n = 2). Although 124 patients underwent anatomic pulmonary resection without complications, non-fatal major or minor complications occurred in 29 (19%) cases: pneumonia, 5 (3%); persistent airleak, 10 (6%); atrial fibrillation, 4 (2%); pulmonary thromboembolism, 2 (1%); urine retention, 2 (1%); wound infection, 2 (1%); postoperative bleeding, 2 (1%); and paralytic ileus, 1 (0.5%).
Composite non-invasive scans (CT, PET-CT) for mediastinal staging showed NPV of 92% (CI 83.6-96.8) in cIA and 85% (CI 74-92) in cIB patients. The 17 (11%) FN cases are reported in Table 2 [6 of 79 (7.6%) cIA and 11 of 74 (14.8%) cIB patients]. Multilevel pN2 were detected in four (5%) cases, all of them in the cIB group. The most frequently involved N2 was subcarinal (two cases) in cIA and R4 and seven (five cases) in cIB (Table 3) .
Occult metastases in mediatinal lymph nodes were more frequent in pathological tumour size ≥5 cm [ pT2b, nine cases; 3.8 (1.3-11.8), P = 0.03]. The pN1 involvement occurred in 9 (11%) cIA and 26 (35%) cIB cases. When these patients are assessed individually, the pN2 rate is significantly higher in this group compared with pN0. Predictive analysis of pN2 risk to identify risk factors is detailed in Tables 4 and 5 . Female sex is the greatest independent risk factor for FN-pN2 in PET-CT (P = 0.018), although it becomes insignificant when this cI stage is split into cIA and cIB (P = 0.15 and 0.052, respectively). Adenocarcinoma is also an independent risk factor (P = 0.029) when other subtypes (LPA and MIA) are excluded. No other risk factors for mediastinal metastases studied (age, clinical stage, tumour location, tumour size, clinical conditions, SUV max of the primitive tumour) showed any significant relationship (P > 0.05). Multilevel pN2 was significantly more frequent in the cIB group (P < 0.03). pN1 detection was significantly less frequent (P < 0.04) in tumour cT ≤ 2 cm than in bigger tumours, without any higher incidence of pN2 in this specific group. In pT ≤ 1 cm (T1a), NPV (100%) was significantly better (P < 0.05) than in the other subgroups studied ( pIA > 1 cm and pIB).
Agreement between clinical and pathological staging in stage I was significantly higher in cIA [62 of 79 (79%), Kappa index 0.67] Table 6 .
DISCUSSION
Integration of PET-CT into the staging algorithm for NSCLC spared 65% of surgical mediastinal staging, essentially due to the high NPV initially reported in comparison to the chest CT scan [16] . In selected cases (stage I, non-central tumours, PET hilar N1 disease or low 18FDG uptake of the primary tumour), this low rate of FNs after negative chest CT scan and PET-CT allowed us to avoid all invasive methods for mediastinal staging and proceed straight to thoracotomy. Furthermore, this strategy reduced to <10% the unexpected N2 detected intraoperatively. After promising beginning and worldwide PET-CT implementation, reports of an abnormally high number of mediastinal FNs in daily clinical practice following these recommendations have raised several doubts [10, 12, 17] . Inaccuracies have been related to PET studies conducted without integrated CT, excessive delay between the PET study and surgery, low 18FDG uptake of the primary tumour and central tumour location, which is believed to have more frequent lymph node involvement [17, 18] and worse accuracy for detecting mediastinal uptake between lymph nodes and central tumours ('hot spot' effect). In addition, various risk factors for unexpected pN2 after negative PET have been identified during the last decade: female sex [12] , current smokers [19] and histology of adenocarcinoma or cN1 [9] .
Tumour size affects survival and has been considered in the new TNM classification; stages I and II have been stratified according to worse prognosis based on larger tumour size. To date, tumour location (central or peripheral) has not been examined as a potential prognostic factor for survival in any TNM stage. Ketchedjian et al. [18] confirmed these suspicions, finding a worse long-term prognosis in early-stage NSCLC (T1N0, 1997 TNM classification) for centrally located compared with peripheral tumour, although without detecting a significant difference in the most advanced stages. Their study used radiographic criteria to define a central tumour, visualized within the inner third of the lung field in a chest X-ray or seen bronchoscopically. For obvious reasons, the criterion is not sufficiently accurate because this very simple approach obtains limited information, especially when the CT scan is routinely performed for all NSCLC diagnoses. In our opinion, implementation of PET-CT must be accompanied by changes in central tumour criteria to optimize the accuracy of this technique. Our study defined the criteria to exclude a central tumour based on CT scan as any tumours in contact with the intrapulmonary main bronchi, pulmonary artery, pulmonary veins or the origin of the first segmental branches of those veins. Thus, the tumours considered central were invasively staged by the most appropriate method and excluded as a potential confounding factor of this study. This strategy is supported by various considerations: the high rate of pN1 expected, avoiding the 'hot spot' effect, the high likelihood of extensive parenchyma resection needed to surgically treat these tumours and the high risk of complications associated with these procedures.
Despite this careful selection, the pN2 intraoperatively detected results >10% for any TNM clinical cut-point for tumour size (≤2 cm, 2 > cT ≤ 5). In this study, we do not find any mediastinal or hilar metastases in pT1a < 1 cm patients. In addition, in cT ≤ 2 cm, the pN1 rate was less frequent, compared with bigger tumours. This low rate of pN1 and pN2 in small peripheral tumours has opened the door to interesting options for sublobar anatomical resections for cT1aN0M0, also supported by other groups [20] . The increasingly frequent detection of tumours <2 cm by screening programmes or as an incidental finding has opened a strong controversy with regard to the most appropriate standard surgical treatment for this steadily increasing patient population. Experience reported in the literature increasingly supports the anatomic segmentectomy as comparable to lobectomy for smaller tumours (≤2 cm) if an acceptable parenchyma margin (>2 cm) is achieved. However, if these tumours are ever suitable for sublobar resection, this should only be considered after thorough intraoperative evaluation of the lobar, hilar and mediastinal lymph nodes.
The best candidates for limited resection are likely to be AIS and MIA patients: these adenocarcinoma subgroups show almost null spreading to the lymph nodes (0/14 pN1 and pN2 in our study) and if totally resected there is good result in local control and long-term survival [15] . On the other hand, after excluding these subgroups, adenocarcinoma is an independent risk factor for pN2 undetected after PET-CT scan. This new classification approach to specimens could be useful to prevent FNs after PET-CT scan in the very few cases in which histology and radiographic correlation is 'almost' beyond any doubt. However, this is unlikely in clinical practices. Therefore, except in patients with small tumours (<2 cm) with very specific radiographic characteristics, limited resection must be an exceptional choice in very carefully selected lung cancer cases. Conversely, the rates of pN1 and pN2 in cIA stage were 9 (11.4%) and 6 (7.6%), respectively, with three (3%) cases of skip metastases. These results make it difficult to offer a limited resection in this selective group of patients if they do not suffer from any limited pulmonary function.
NSCLC prevalence in women is dramatically increasing, essentially due to increased tobacco use among women in Spain. Although controversial, it appears that women might be more susceptible to the carcinogenic effects of tobacco than men [21] . However, one in five women in western countries never smoked and 70-80% of non-smoking Asiatic patients suffering from NSCLC were women with other related genetic factors (e.g. epidermal growth factor mutation) [22] . The most frequent NSCLC histology in women is adenocarcinoma, and AIS is 2-4 times more likely in women than men. This could explain the better prognosis linked to female sex, particularly in advanced disease regardless of treatment modality, stage, age or any other characteristics [23] . In our series, female patients were elderly, without hormonal cycle or hormonal replacement therapy, which (despite the controversy) appears to be a significant risk factor for NSCLC mortality [24] . Sex-based variations in mutation rates of multiple regulating gene pathways as well as differences in DNA repair capacity and hormonal factors have all been implicated in the clinical disparity evident between men and women in presentation, course, treatment response and survival after NSCLCs [21] .
Unfortunately, we identified no other preoperative clinical characteristics (e.g. SUV max ) or any location other than female sex and adenocarcinoma that could be useful to prevent occult mediastinal node involvement. In our study, larger cT size (cT1a to cT2a) was not significantly related to more occult incidence of pN2. However, more than one affected pN2 station was only found in the cIB stage. This result was a relief to our physicians, oncologists and thoracic surgeons because, despite PET-CT inaccuracies, very few and perhaps none of these cI patients 'spared' from invasive studies under our study protocol 'should have been' assigned to another treatment modality. A PET-CT scan together with CT scanning correctly staged fewer than 65% of stage cIA cases using the 1997 TMN [11] ; in our study using the new 2009 TNM, this rate was even lower in clinical stage cI, with only 44% of the patients correctly staged. This level of accuracy, although perhaps acceptable in cIA (77%), leads to an incorrect pStage in more than half (56%) of the cIB cases assessed. Upstaging after PET-CT in these early clinical stages was more frequent as tumour size increased. It seems clear that the new TNM 2009 guidelines offer a better correlation between clinical and pathological aspects in stage I, essentially because tumours of between 5 and 7 cm in size progress to stage cIIA.
The main strength of this prospective study is to identify a particular non-central stage pI NSCLC group ( pIB, pT2b) with a high rate of unexpected N2. In addition, the higher mediastinal node involvement in female and adenocarcinoma patients demonstrated in the cI stage suggests the need for careful, individualized selection in this group when we consider avoiding invasive staging. As suggested in our previous work [12] , integrating PET-CT into the pre-treatment algorithm needs to be redefined in several groups in which mediastinal node involvement is crucial in achieving reasonable long-term survival.
Unfortunately, except for women and adenocarcinoma, these groups are not yet properly defined. Further prospective studies are needed, including more early-stage subjects who are potential candidates to avoid invasive mediastinal procedures.
